This study is in progress, not accepting new patients
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Fresno, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Ramin Sam
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Ramin Sam
College: University of Illinois-Urbana Medical School: University of Illinois-Chicago Internal Medicine Residency: Loyola University Nephrology Fellowship: Loyola University Interests: My clinical/research interests are varied and include sodium disorders, hemodialysis, acid/base disorders, transjugular kidney biopsies and lipoprotein glomerulonephropathy.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bayer
- ID
- NCT02545049
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated